Breath analysis using VOCs shows promise for early NSCLC diagnosis, achieving 85% accuracy, 86.7% sensitivity, and 83.3% specificity. Current lung cancer diagnostic methods are invasive and costly, ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released three additional case studies -- ...
India Today on MSN
Lung cancer screening with low-dose CT can save lives, say experts
With most lung cancers in India diagnosed at advanced stages, experts say low-dose CT screening for high-risk groups like ...
Everyday Health’s team of board-certified physicians and health professionals contribute to the creation and review of content, ensuring that the information is useful, up to date, and accurate. A ...
Lung (pulmonary) sarcoma is a rare type of lung cancer. Most lung cancers start in epithelial cells that line your airways, but pulmonary sarcoma develops in connective tissue or other nonepithelial ...
A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance ...
A 60-year-old’s routine health screening revealed stage 1 lung cancer – a reminder that the disease can strike anyone, and ...
Noninvasive diagnostic test again leads to detecting Stage 1A lung cancer SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (Nasdaq: BIAF; BIAFW), a biotechnology company advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback